BRIEF-PCI: Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention
Coronary Artery Disease, Myocardial Infarction
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring Percutaneous Coronary Intervention (PCI), Glycoprotein IIb/IIIa blockade, Ischemic complications following PCI
Eligibility Criteria
Inclusion Criteria: Male and non-pregnant female subjects 18 years of age or older Received aspirin, clopidogrel, heparin (unfractionated or low molecular weight [LMW]) and eptifibatide Had a successful PCI procedure with at least one stent deployed Availability of a hospital bed Exclusion Criteria: Use of alternative anti-thrombin therapy during PCI (e.g. bivalirudin) High risk patients: Acute ST elevation MI < 48 hours (either direct PCI or rescue PCI) Unprotected left main PCI Obvious large thrombus on angiography Use of rotablation, atherectomy, or thrombectomy devices Unsatisfactory PCI results: Final thrombolysis in myocardial infarction (TIMI) flow < 3 High grade dissection (> type B, if not completely resolved at completion of PCI) Evident or suspected thrombus Distal embolization Suboptimal stenting (> 20% residual stenosis) Side branch closure (≥ 1.5 mm branch or with associated symptoms) Abrupt closure during procedure (if prolonged > 15 min or not resolved at completion of PCI) Clinical instability Prolonged ischemia during PCI (> 15 min) Increased hazard of eptifibatide infusion: Unsatisfactory deployment of a closure device (if used) Large peri-procedure hematoma making the continuation of eptifibatide hazardous Any condition that will increase the hazard of continuing eptifibatide Operator discretion No informed consent Active participation in other research studies (unless with special exemption)
Sites / Locations
- Vancouver General Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
18 Hour infusion
4 hour infusion